Cargando…
A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer
BACKGROUND: The clinical challenges of triple-negative breast cancer (TNBC) includes the lack of targeted therapy and chemoresistance. TNBC has relatively high PD-L1 expression, and PD-L1 antibody in combination with nab-paclitaxel has been approved by FDA for TNBC treatment. Aptamers, also termed c...
Autores principales: | Wu, Xiaoqiu, Li, Fangfei, Li, Yongshu, Yu, Yuanyuan, Liang, Chao, Zhang, Baoting, Zhao, Chuanzong, Lu, Aiping, Zhang, Ge |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331476/ https://www.ncbi.nlm.nih.gov/pubmed/32574155 http://dx.doi.org/10.12659/MSM.925583 |
Ejemplares similares
-
Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine
por: Zhuo, Zhenjian, et al.
Publicado: (2017) -
Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells
por: Fan, Li-li, et al.
Publicado: (2020) -
Hyperglycemia Promotes Liver Metastasis of Colorectal Cancer via Upregulation of Integrin αvβ6
por: Wang, Ben, et al.
Publicado: (2021) -
A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer
por: Li, Fangfei, et al.
Publicado: (2017) -
Altered Mitochondrial Dynamics, Biogenesis, and Functions in the Paclitaxel-Resistant Lung Adenocarcinoma Cell Line A549/Taxol
por: Zhou, Xiang, et al.
Publicado: (2020)